AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

75 76 Next >

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

April 05, 2024

From AstraZeneca

Via Business Wire

A Closer Look at AstraZeneca's Options Market Dynamics ↗

April 03, 2024

Via Benzinga

AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race ↗

April 02, 2024

AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over...

Via Benzinga

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

April 02, 2024

From AstraZeneca

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

April 01, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

April 01, 2024

From Alexion

Via Business Wire

7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years ↗

March 28, 2024

These are the blue-chip stocks to outperform Dow in the next five years and represents companies with growth and cash flow visibility.

Via InvestorPlace

Topics Stocks

Bull Market Buys: 3 Dividend Stocks to Own for the Long Run ↗

March 28, 2024

Invest in stability, dividends, and growth with these three accomplished real estate operators.

Via The Motley Fool

What's Going On European Pharma Giant AstraZeneca Stock On Wednesday? ↗

March 27, 2024

Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca...

Via Benzinga

Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave

March 26, 2024

Via AB Newswire

Topics Intellectual Property

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)

March 25, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

March 25, 2024

From Alexion

Via Business Wire

Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum

March 22, 2024

Via AB Newswire

Topics Artificial Intelligence Intellectual Property

EXCLUSIVE: 2024 Witnesses Increase In Biotech Initial Public Offerings ↗

March 21, 2024

Dr. Laura Chico, Senior VP at Wedbush, is optimistic about 2024 biotech IPO market and M&A trends. Election year may affect performance.

Via Benzinga

Topics Initial Public Offering

After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study ↗

March 21, 2024

Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression.

Via Benzinga

Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month ↗

March 21, 2024

GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...

Via Benzinga

3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar ↗

March 20, 2024

These are the stagnating blue-chip stocks to buy at undervalued levels, as they represent fundamentally strong ideas with healthy cash flows.

Via InvestorPlace

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗

March 19, 2024

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –

March 19, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover ↗

March 19, 2024

The company is working on radiopharmaceuticals treatments for cancer.

Via Investor's Business Daily

Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today? ↗

March 19, 2024

Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 19, 2024

Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news worth reading about this morning!

Via InvestorPlace

AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments ↗

March 19, 2024

AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...

Via Benzinga

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

March 19, 2024

From AstraZeneca

Via Business Wire

AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer ↗

March 18, 2024

AstraZeneca's latest analysis on Imfinzi plus chemotherapy followed by Imfinzi plus Lynparza in endometrial cancer. Improved secondary efficacy endpoints in patients with advanced or recurrent...

Via Benzinga

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

March 18, 2024

From AstraZeneca

Via Business Wire

7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million ↗

March 15, 2024

These million dollar mega-cap stocks will continue to produce big winners in 2024 and beyond as they continue to rise.

Via InvestorPlace

Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus ↗

March 14, 2024

Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target...

Via Benzinga

AstraZeneca Beefs Up Its Endocrine Disease Pipeline With Amolyt Pharma Deal Worth $1.05B ↗

March 14, 2024

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion, expanding rare disease pipeline with eneboparatide (AZP-3601), a Phase 3 investigational peptide for hypoparathyroidism.

Via Benzinga

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗

March 13, 2024

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

Via InvestorPlace

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.